Garza-Garza Lucas A, Ruiz-Lozano Raúl E, Rebolledo-Méndez Genaro, Ibarra-Nava Ismael, Morales-Garza Héctor J, Ancona-Lezama David
Tecnologico de Monterrey, School of Medicine and Health Sciences, Ocular Oncology Service at Institute of Ophthalmology and Visual Sciences, Hospital Zambrano-Hellion, San Pedro Garza Garcia, Nuevo León, Mexico.
Writing Lab, TecLabs, Vicerrectoria de Investigación y Transferencia de Tecnología, Tecnologico de Monterrey, Monterrey, Mexico.
J Ophthalmol. 2020 Aug 10;2020:1953602. doi: 10.1155/2020/1953602. eCollection 2020.
Early diagnosis and positive outcomes of retinoblastoma in childhood have been positively correlated with the economic wealth of high-income countries (HICs) worldwide. Adequate curability and survival rates, adherence to treatment, presence of poor prognostic initial clinical signs, and metastatic disease at diagnosis appear to have a less favorable picture in low-income countries (LICs). However, this is not always the case. An example is Argentina, where disease-free survival rates of retinoblastoma are notably higher than expected when taking into consideration its economic situation. Unfortunately, as in other Latin American LICs, retinoblastoma outcomes in Mexico are worrisome. Interestingly, the Human Development Index (HDI) in Mexico varies widely between its different geographical regions. While in some states, the HDI resembles those of high-income countries, and in others, the opposite is observed. A unifying picture of Mexico's developmental status, health resources, indicators, and other factors possibly influencing outcomes in retinoblastoma is currently unavailable. The present review explores the previously mentioned factors in Mexico and compares them to other countries. Additionally, it recommends solutions or enhancements where possible.
儿童视网膜母细胞瘤的早期诊断和良好预后与全球高收入国家(HICs)的经济财富呈正相关。在低收入国家(LICs),治愈率和生存率是否足够、对治疗的依从性、诊断时预后不良的初始临床体征的存在以及转移性疾病,情况似乎不太乐观。然而,情况并非总是如此。阿根廷就是一个例子,考虑到其经济状况,视网膜母细胞瘤的无病生存率明显高于预期。不幸的是,与其他拉丁美洲低收入国家一样,墨西哥视网膜母细胞瘤的治疗结果令人担忧。有趣的是,墨西哥的人类发展指数(HDI)在其不同地理区域之间差异很大。在一些州,HDI与高收入国家相似,而在其他州则相反。目前尚无法全面了解墨西哥的发展状况、卫生资源、指标以及其他可能影响视网膜母细胞瘤治疗结果的因素。本综述探讨了墨西哥上述因素,并与其他国家进行了比较。此外,它还在可能的情况下推荐了解决方案或改进措施。